Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Neurogastroenterol Motil. 2020 Nov;32(11):e13891. doi: 10.1111/nmo.13891. Epub 2020 May 25.
BACKGROUND: Little is known about intestinal fungi in IBS patients whose gut bacteria have been investigated a lot. In order to explore causal relationship between IBS and gut mycobiome, and use gut fungi to diagnose or even treat IBS, further characterization of it in IBS is required. METHODS: Fifty-five diarrhea-predominant IBS (D-IBS) patients fulfilling Rome III criteria, and 16 healthy controls (HC) were recruited. Fresh fecal samples were collected and used for 16s rRNA and ITS2 high-throughput sequencing. Diversity and composition of gut bacteria and fungi, as well as bacterial-fungal interactions in D-IBS patients, were characterized. Specific fungal taxa differentiating D-IBS from HC were recognized by LEfSe and RandomForest methods, and their association with clinical symptoms was assessed by Spearman's correlation. RESULTS: Diarrhea-predominant irritable bowel syndrome patients showed abnormal (IBS-dysbiosis) or normal (HC-like IBS) fecal bacterial structure and diversity compared with healthy controls. However, fecal fungal signatures differed absolutely between D-IBS and HC, which indicated a more susceptible alteration of gut fungi than bacteria in D-IBS. Fecal fungi showed significant correlations with IBS symptoms, especially Mycosphaerella, Aspergillus, Sporidiobolus, and Pandora which were identified to potentially differentiate D-IBS from HC. Moreover, compared with HC there were markedly declined bacterial-fungal interactions in D-IBS, in which Candida changed from negative to positive correlations with bacteria, and Eurotium changed from positive correlations to irrelevance, while Debaryomyces gained negative correlations with bacteria. CONCLUSIONS: Gut fungal dysbiosis and altered bacterial-fungal interactions were present in patients with D-IBS, and gut fungi could be used to diagnose D-IBS.
背景:虽然已经对大量的肠道细菌进行了研究,但对于肠内真菌在 IBS 患者中的情况知之甚少。为了探索 IBS 与肠道真菌组之间的因果关系,并利用肠道真菌进行诊断甚至治疗 IBS,需要进一步对 IBS 中的肠道真菌进行研究。
方法:招募了 55 名符合罗马 III 标准的腹泻型肠易激综合征(D-IBS)患者和 16 名健康对照(HC)。采集新鲜粪便样本进行 16s rRNA 和 ITS2 高通量测序。分析 D-IBS 患者肠道细菌和真菌的多样性和组成,以及细菌-真菌相互作用。通过 LEfSe 和 RandomForest 方法识别区分 D-IBS 和 HC 的特定真菌类群,并通过 Spearman 相关性评估其与临床症状的相关性。
结果:与健康对照组相比,腹泻型肠易激综合征患者的粪便细菌结构和多样性出现异常(IBS 失调)或正常(类似 HC 的 IBS)。然而,D-IBS 和 HC 之间的粪便真菌特征绝对不同,这表明肠道真菌在 D-IBS 中的变化比细菌更敏感。粪便真菌与 IBS 症状密切相关,特别是 Mycosphaerella、Aspergillus、Sporidiobolus 和 Pandora,这些真菌被认为可以潜在地区分 D-IBS 和 HC。此外,与 HC 相比,D-IBS 中细菌-真菌相互作用明显减少,其中 Candida 与细菌的相关性由负变正,Eurotium 由正相关变为无关,而 Debaryomyces 与细菌的相关性变为负相关。
结论:D-IBS 患者存在肠道真菌失调和细菌-真菌相互作用改变,肠道真菌可用于诊断 D-IBS。
Clin Transl Gastroenterol. 2020-3
J Gastroenterol Hepatol. 2018-2-26
Orphanet J Rare Dis. 2025-5-2
J Fungi (Basel). 2025-4-2
Front Med (Lausanne). 2025-2-13
Mycopathologia. 2023-12
Life (Basel). 2023-3-31
Front Vet Sci. 2022-10-28